135 related articles for article (PubMed ID: 8737633)
41. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis].
Janda K; Stompór T; Gryz E; Szczudlik A; Drozdz M; Kraśniak A; Sułowicz W
Przegl Lek; 2007; 64(6):423-30. PubMed ID: 18159852
[TBL] [Abstract][Full Text] [Related]
42. [Incidence of chronic renal failure during 35 years at the Rijeka Clinical Hospital Center].
Orlić L; Matić-Glazar D; Vlahović A; Zivcić-Cosić S; Maleta I; Martinović BS; Racki S; Madzar Z
Acta Med Croatica; 2004; 58(1):73-7. PubMed ID: 15125398
[TBL] [Abstract][Full Text] [Related]
43. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
[TBL] [Abstract][Full Text] [Related]
44. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
Pellicano R; Polkinghorne KR; Kerr PG
Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
[TBL] [Abstract][Full Text] [Related]
45. The current state of chronic dialysis treatment in Japan (as of December 31, 2000).
Ther Apher Dial; 2003 Feb; 7(1):3-35. PubMed ID: 12921111
[TBL] [Abstract][Full Text] [Related]
46. [Effect of the vasoactive drug buflomedil in arterial occlusive disease].
Racenberg J; Intaglietta M; Messmer K
Fortschr Med; 1982 Nov; 100(41):1926-30. PubMed ID: 7152426
[TBL] [Abstract][Full Text] [Related]
47. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
[TBL] [Abstract][Full Text] [Related]
48. [Flowmetric, thermometric and rheologic studies in obliterating arterial diseases of the lower extremities treated with buflomedil].
Dorigo B; Raspanti D; Trapani M; Albanese B; Cameli AM; Digiesi V
Minerva Med; 1985 Feb; 76(7):269-75. PubMed ID: 3974940
[TBL] [Abstract][Full Text] [Related]
49. [Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
Grzegorzewska A; Lowicki Z; Chmara E; Mrozikiewicz A; Baczyk K
Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):339-41. PubMed ID: 2235722
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of chronic cerebrovascular insufficiency and chronic obliterating arteriopathy of the lower extremities with buflomedil hydrochloride].
Salerno L; Sallì L; Pepe S; Curiale B; Allegra G; Scalici G; Salvato F
Minerva Med; 1985 Sep; 76(36):1611-8. PubMed ID: 4047447
[TBL] [Abstract][Full Text] [Related]
51. The effect of buflomedil in diabetic retinopathy estimated by ocular fluorophotometry.
Kjaergaard JJ; Ditzel J
Int J Microcirc Clin Exp; 1987 Aug; 6(3):257-63. PubMed ID: 3308731
[TBL] [Abstract][Full Text] [Related]
52. Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin.
Cucinotta D; Aveni Casucci MA; Pedrazzi F; Ponari O; Capodaglio M; Valdina P; Toxiri I; Bartorelli L; Granata Q; Franzini C
J Int Med Res; 1992 Apr; 20(2):136-49. PubMed ID: 1521670
[TBL] [Abstract][Full Text] [Related]
53. Increase in plasma levels of adenosine and adenine nucleotides after intravenous infusion of buflomedil in humans.
Capecchi PL; Laghi Pasini F; Sodi N; Chiavetta M; Sensi S; De Lalla A; Volpi L; Di Perri T
J Cardiovasc Pharmacol; 1995 Jan; 25(1):35-9. PubMed ID: 7723351
[TBL] [Abstract][Full Text] [Related]
54. An experimental overview of a new vasoactive drug: buflomedil HCl.
Dubourg A; Scamuffa RF
Angiology; 1981 Oct; 32(10):663-75. PubMed ID: 7034590
[TBL] [Abstract][Full Text] [Related]
55. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.
Clissold SP; Lynch S; Sorkin EM
Drugs; 1987 May; 33(5):430-60. PubMed ID: 3297620
[TBL] [Abstract][Full Text] [Related]
56. [Value of buflomedil in vascular radiology of hepatoma].
Emery JC; Genin G; Bonvoisin S; Croisille M
Ann Radiol (Paris); 1994; 37(6):441-8. PubMed ID: 7702337
[TBL] [Abstract][Full Text] [Related]
57. Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011.
Bucolo C; Longo L; Camillieri G; Drago F; Salomone S
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1190-6. PubMed ID: 22855302
[TBL] [Abstract][Full Text] [Related]
58. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
Sunder-Plassmann L; Gandolfo AM; Utz C
MMW Munch Med Wochenschr; 1984 Mar; 126(9):247-8. PubMed ID: 6425678
[No Abstract] [Full Text] [Related]
59. [Effect of buflomedil on microcirculation of the skin in acral gangrene].
Fagrell B; Hermansson IL
Fortschr Med; 1985 Jan; 103(1-2):23-7. PubMed ID: 3882535
[No Abstract] [Full Text] [Related]
60. The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration.
Gundert-Remy U; Weber E; Lam G; Chiou WL; Mann W; Aynilian GH
Eur J Clin Pharmacol; 1981; 20(6):459-63. PubMed ID: 7286057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
